Key result
Panax ginseng significantly reduced doxorubicin-induced myocardial injury in experimental rats, lowering cardiac troponin I levels by 9.89 ng/L compared to doxorubicin alone.
Why the study?
Doxorubicin is an effective broad-spectrum anti-cancer drug, but its clinical use can be limited by cardiotoxicity.
Does Panax ginseng reduce doxorubicin-induced cardiotoxicity in male Sprague Wistar rats?
Does Panax ginseng reduce doxorubicin-induced cardiotoxicity in male Sprague Wistar rats?
Panax ginseng attenuates doxorubicin-induced cardiotoxicity in a rat model by suppressing oxidative stress, inflammatory, and apoptotic pathways.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ginseng in doxorubicin cardiotoxicity; requires human trials before any clinical consideration.
BACKGROUND: Doxorubicin (DOX) is a broad-spectrum anti-cancer drug that is used to treat a variety of cancers, including blood cancers such as leukemia and solid tissue cancers. However, its use some time limited because of its cardiotoxicity. OBJECTIVE: The objective of the study was to determine the cardioprotective effect of ginseng in the case of cardiotoxicity caused by doxorubicin therapy. Methods: Thirty experimental animals (male Sprague Wistar rats) were used in this research and they were separated into three groups: Rats in Group I (n# = 10) were given distilled water plus normal saline, rats in Group II (n# = 10) were given distilled water plus doxorubicin, and rats in Group III (n# = 10) were given Panax ginseng plus doxorubicin. Serum concentration, malondialdehyde (MDA), glutathione reductase (GSH), lipid peroxidase (LPO), TNF (ng/L), cardiac troponin (ng/L), brain natriuretic peptide BNP(g/L), and caspase-3 (pmol/L) levels were measured in all groups. RESULTS: Doxorubicin caused substantial cardiotoxicity as a result of a significant increase in the elevation of cTnI to 40.09 ± 6.67 (ng/L). In addition, MDA, LPO, TNF-α, and caspase-3 levels were increased in doxorubicin group compared to the control group p < 0.05. Panax ginseng reduced cardiac troponin (cTnI) However, its effect on reduction of BNP levels insignificantly compared to the doxorubicin group p = 0.06. Panax ginseng reduced LPO and MDA and raised the antioxidant potential biomarker GSH significantly compared to the doxorubicin group p < 0.05. Panax ginseng significantly reduced inflammatory (TNF-α) and apoptotic (caspase-3) biomarkers when compared to the doxorubicin group. CONCLUSIONS: According to the findings of this study, Panax ginseng suppresses reactive oxygen species and inflammatory and apoptotic pathways in experimental rats, thereby preventing doxorubicin-induced cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Al-Hussaniy et al. (2022) studied Doxorubicin-induced cardiotoxicity (n=30). Panax ginseng vs. Doxorubicin alone (20 mg/kg) was evaluated on Cardiac troponin I (cTnI) levels (MD -9.89, 95% CI -15.70-4.07, p=0.002). Panax ginseng significantly reduced doxorubicin-induced myocardial injury in experimental rats, lowering cardiac troponin I levels by 9.89 ng/L compared to doxorubicin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: